Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 30

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Rheumatoid arthritis

Not recruiting

Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Janssen - Cilag International

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Plasma cell myeloma

Not recruiting

Study on Venetoclax, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Gingival bleeding+1

Not recruiting

Study on Tranexamic Acid Oral Solution for Preventing Bleeding in Patients on Blood Thinners Undergoing Tooth Extraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Hyloris Developments

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Plaque Psoriasis in Special Areas for Patients with Moderate to Severe Symptoms

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Pyoderma gangrenosum

Not recruiting

Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:InflaRx GmbH

Asthma

Not recruiting

Study on Tezepelumab for Children Aged 5 to 11 with Severe Asthma

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Tezepelumab
  • Sponsor:Astrazeneca AB

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.